Business Description
Tatva Chintan Pharma Chem Ltd
ISIN : INE0GK401011
Compare
Compare
Traded in other countries / regions
543321.India IPO Date
2021-07-29Description
Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacturing and selling of specialty chemicals, Pharma and Agro intermediates, Quaternary Compounds, and Quats. The company's product portfolio includes structure-directing agents, phase transfer catalysts, electrolyte salts for supercapacitor batteries, pharmaceutical and agrochemical intermediates and other specialty chemicals. The company sells its products in domestic as well as overseas markets, with the majority of revenue coming from overseas markets.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.01 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.3 | |||||
| Interest Coverage | 28.75 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 17.3 | |||||
| Beneish M-Score | -2.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.4 | |||||
| 3-Year EBITDA Growth Rate | 0.7 | |||||
| 3-Year EPS without NRI Growth Rate | -17.4 | |||||
| 3-Year FCF Growth Rate | -171.4 | |||||
| 3-Year Book Growth Rate | 61.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 63.46 | |||||
| Future 3-5Y Total Revenue Growth Rate | 29.05 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.84 | |||||
| 9-Day RSI | 43.23 | |||||
| 14-Day RSI | 43.93 | |||||
| 6-1 Month Momentum % | -27.26 | |||||
| 12-1 Month Momentum % | -47.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.69 | |||||
| Quick Ratio | 1.56 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 285.27 | |||||
| Days Sales Outstanding | 64.63 | |||||
| Days Payable | 60.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.24 | |||||
| Dividend Payout Ratio | 0.26 | |||||
| Forward Dividend Yield % | 0.24 | |||||
| 5-Year Yield-on-Cost % | 0.25 | |||||
| 3-Year Average Share Buyback Ratio | -1.8 | |||||
| Shareholder Yield % | 5.55 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.02 | |||||
| Operating Margin % | 5.44 | |||||
| Net Margin % | 4.78 | |||||
| FCF Margin % | -8.27 | |||||
| ROE % | 2.4 | |||||
| ROA % | 2.14 | |||||
| ROIC % | 1.99 | |||||
| ROC (Joel Greenblatt) % | 3.76 | |||||
| ROCE % | 3.45 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 112.58 | |||||
| Forward PE Ratio | 31.39 | |||||
| PE Ratio without NRI | 112.14 | |||||
| Price-to-Owner-Earnings | 127.55 | |||||
| PEG Ratio | 9.92 | |||||
| PS Ratio | 5.37 | |||||
| PB Ratio | 2.7 | |||||
| Price-to-Tangible-Book | 2.71 | |||||
| Price-to-Operating-Cash-Flow | 19.84 | |||||
| EV-to-EBIT | 78.22 | |||||
| EV-to-EBITDA | 38.44 | |||||
| EV-to-Revenue | 5.4 | |||||
| EV-to-FCF | -62.51 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.64 | |||||
| Price-to-Graham-Number | 3.68 | |||||
| Price-to-Net-Current-Asset-Value | 11 | |||||
| Earnings Yield (Greenblatt) % | 1.27 | |||||
| FCF Yield % | -1.53 | |||||
| Forward Rate of Return (Yacktman) % | 8.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tatva Chintan Pharma Chem Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,684.17 | ||
| EPS (TTM) (₹) | 7.55 | ||
| Beta | 0.82 | ||
| Volatility % | 39.7 | ||
| 14-Day RSI | 43.93 | ||
| 14-Day ATR (₹) | 28.610036 | ||
| 20-Day SMA (₹) | 877.5625 | ||
| 12-1 Month Momentum % | -47.48 | ||
| 52-Week Range (₹) | 789.05 - 1647.95 | ||
| Shares Outstanding (Mil) | 23.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tatva Chintan Pharma Chem Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tatva Chintan Pharma Chem Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tatva Chintan Pharma Chem Ltd Frequently Asked Questions
What is Tatva Chintan Pharma Chem Ltd(BOM:543321)'s stock price today?
The current price of BOM:543321 is ₹850.00. The 52 week high of BOM:543321 is ₹1647.95 and 52 week low is ₹789.05.
When is next earnings date of Tatva Chintan Pharma Chem Ltd(BOM:543321)?
The next earnings date of Tatva Chintan Pharma Chem Ltd(BOM:543321) is 2025-01-20 Est..
Does Tatva Chintan Pharma Chem Ltd(BOM:543321) pay dividends? If so, how much?
The Dividend Yield %  of Tatva Chintan Pharma Chem Ltd(BOM:543321) is 0.24% (As of Today), Highest Dividend Payout Ratio of Tatva Chintan Pharma Chem Ltd(BOM:543321) was 0.26. The lowest was 0.09. And the median was 0.12. The  Forward Dividend Yield % of Tatva Chintan Pharma Chem Ltd(BOM:543321) is 0.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers